

To: AmeriHealth Caritas DC Providers

Date: April 29, 2021

Subject: Buprenorphine Prescribing Updates for Opioid Use Disorder

The Substance Abuse and Mental Health Services Administration (SAMHSA) has issued new practice guidelines for prescribing buprenorphine for opioid use disorder. Effective April 28, 2021, eligible practitioners will be able to obtain an X waiver by submitting a Notice of Intent (NOI) to prescribe buprenorphine to 30 or fewer patients. The new guidelines exempt eligible practitioners from certification requirements related to training and the provision of psychosocial services, which were previously necessary when dispensing or prescribing buprenorphine for the treatment of opioid use disorder.

For more information, please visit <u>https://www.samhsa.gov/medication-assisted-</u>treatment/practitioner-resources/faqs.